Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 29;9(8):ofac382.
doi: 10.1093/ofid/ofac382. eCollection 2022 Aug.

Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection

Mario A Martinez  1 , Ting-Yi Chen  2 , Hosoon Choi  3 , Munok Hwang  3 , Dhammika Navarathna  4 , Linhue Hao  5 , Michael Gale Jr  5 , Gregory Camus  6 , Hector E Ramirez  1 , Chetan Jinadatha  2
Affiliations

Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection

Mario A Martinez et al. Open Forum Infect Dis. .

Abstract

Persistent severe acute respiratory syndrome coronavirus 2 infection is difficult to treat. Here, we report a case of 5-month persistent coronavirus disease 2019 in an immunocompromised patient who was successfully treated with 30 consecutive days of remdesivir. Prolonged remdesivir infusion with concurrent cycle threshold monitoring might provide a potential solution to cure these patients with difficult-to-treat infections.

Keywords: Ct value; persistent COVID-19; prolonged remdesivir; remdesivir mutation; remdesivir resistance.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Clinical response to standard and extended infusions of remdesivir with corresponding cycle threshold values. Abbreviation: HD, hospital day.
See this image and copyright information in PMC

References

    1. Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 2020; 383:2291–3. - PMC - PubMed
    1. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med 2020; 383:2586–8. - PMC - PubMed
    1. Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis 2020; 222:1103–7. - PMC - PubMed
    1. Vermillion MS, Murakami E, Ma B, et al. Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection. Sci Transl Med 2022; 14:eabl8282. - PMC - PubMed
    1. Biancofiore A, Mirijello A, Puteo MA, et al. Remdesivir significantly reduces SARS-CoV-2 viral load on nasopharyngeal swabs in hospitalized patients with COVID-19: a retrospective case-control study. J Med Virol 2022; 94:2284–9. - PMC - PubMed